Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium-dependent neutral amino acid transporter B(0)AT1 is a membrane protein encoded by the SLC6A19 gene. It mediates the sodium-dependent uptake and epithelial resorption of all neutral amino acids across the apical membrane in both kidney and intestinal epithelial cells. This function is critical for maintaining systemic levels of essential and non-essential neutral amino acids. For proper surface expression and catalytic activity, B(0)AT1 requires coexpression with collectrin (TMEM27). Mutations in this gene cause Hartnup disease, a disorder characterized by defective transport of certain amino acids leading to various clinical symptoms. The transporter has also been identified as a possible therapeutic target for metabolic diseases such as type 2 diabetes due to its central role in nutrient handling. Benztropine has been shown experimentally to act as a selective competitive inhibitor of this transporter.
Competitive inhibition of sodium-dependent uptake of neutral amino acids by blocking the transporter’s substrate binding site
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19 (also known as B0AT1)).